Actively Recruiting
Heart Attack Research Program: Platelet Sub-Study (HARP)
Led by NYU Langone Health · Updated on 2026-04-20
350
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.
CONDITIONS
Official Title
Heart Attack Research Program: Platelet Sub-Study (HARP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute ischemic symptoms compatible with myocardial infarction, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
- Objective evidence of myocardial infarction by elevated troponin above laboratory upper limit or ST segment elevation ≥1mm on 2 contiguous ECG leads
- Willingness to provide informed consent and comply with protocol
- Administration of aspirin at least 1 hour before cardiac catheterization
- Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization
- Women and men with ≥50% stenosis of any major epicardial vessel on invasive angiography may participate
You will not qualify if you...
- Recent use (within 1 month) of vasospastic agents such as cocaine, triptans, or ergot alkaloids
- Alternate explanations for troponin elevation including hypertensive urgency, acute heart failure exacerbation, chronic kidney disease elevation, pulmonary embolism, or cardiac trauma
- Pregnancy
- Thrombolytic therapy for STEMI at qualifying event
- Use of platelet antagonists (except aspirin and thienopyridines) within 7 days
- Use of NSAIDs (e.g., ibuprofen, naproxen) within 3 days
- Thrombocytopenia (platelet count <100,000)
- Thrombocytosis (platelet count >500,000)
- Anemia with hemoglobin <9 mg/dl
- Hemorrhagic diathesis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Medical Center
New York, New York, United States, 10016
Actively Recruiting
Research Team
J
Jeffrey Berger, MD
CONTACT
H
Harmony R Reynolds, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here